Amarin Corp Plcuk (AMRN) Research & Development (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Research & Development of $1.5 million for Q1 2026, down 25.51% YoY from $2.0 million in Q1 2025, and down 71.68% sequentially from $5.4 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Research & Development (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Research & Development across 17 years of filings, most recently posting $1.5 million for Q1 2026.
- In Q1 2026, Research & Development fell 25.51% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $13.1 million (up 715.95% YoY), while the FY2025 annual figure was $19.8 million, up 139.32% from the prior year.
- Research & Development retreated to $1.5 million in Q1 2026, from $5.4 million in the prior quarter.
- Over the last five years, Research & Development for AMRN reached as high as $10.1 million in Q1 2022 and fell as low as -$7.4 million in Q4 2022.
- The 5-year median for Research & Development is $4.9 million (2025), against an average of $2.8 million.
- Annual changes were most pronounced in 2022 — Research & Development tumbled 228.73% — and 2025, when it surged 181.28%.
- A 5-year view of Research & Development shows it stood at -$7.4 million in 2022, then rose by 3.35% to -$7.2 million in 2023, then advanced by 7.68% to -$6.6 million in 2024, then soared by 181.28% to $5.4 million in 2025, then tumbled by 71.68% to $1.5 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $1.5 million, $5.4 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 3.51 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 3.53 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 2.47 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -3.49 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 12.59 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.72 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 1.37 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 2.49 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | 1.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.52 Mn |
| Dec 31, 2025 | 5.37 Mn |
| Sep 30, 2025 | 1.29 Mn |
| Jun 30, 2025 | 4.92 Mn |
| Mar 31, 2025 | 2.04 Mn |
| Dec 31, 2024 | -6.61 Mn |
| Sep 30, 2024 | 1.43 Mn |
| Jun 30, 2024 | 4.75 Mn |
| Mar 31, 2024 | 5.60 Mn |
| Dec 31, 2023 | -7.16 Mn |
| Sep 30, 2023 | 5.11 Mn |
| Jun 30, 2023 | 5.64 Mn |
| Mar 31, 2023 | 5.68 Mn |
| Dec 31, 2022 | -7.41 Mn |
| Sep 30, 2022 | 5.77 Mn |
| Jun 30, 2022 | 9.36 Mn |
| Mar 31, 2022 | 10.05 Mn |
| Dec 31, 2021 | 5.75 Mn |
| Sep 30, 2021 | 7.82 Mn |
| Jun 30, 2021 | 6.36 Mn |